Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

The FDA on Thursday approved daratumumab-hyaluronidase (Darzalex Faspro) as the first drug for high-risk smoldering multiple ...

Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

Stem cell transplant options have expanded, utilizing matched siblings, unrelated donors, and umbilical cord blood, enhancing access for hematologic cancer patients. October brought developments in ...

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Multiple myeloma remains an incurable blood cancer, with nearly all patients relapsing and requiring subsequent therapy ...

Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...

Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...

Kimberly Alexander's caregiving experience revealed a lack of awareness and support for multiple myeloma, especially in the ...